| Schedule of Significant Revenue and Expense Categories of the Company’s Single Operating Segment |
The following table presents the significant revenue and expense categories of the Company’s single operating segment.
|
|
|
For the three months ended
September 30,
|
| |
|
2025
|
|
2024
|
| |
|
(Unaudited)
|
|
(Unaudited)
|
|
Operating expenses:
|
|
|
|
|
|
|
|
Clinical trial related service fee
|
|
$
|
4,125,000 |
|
$
|
2,801,000 |
|
Consulting fee
|
|
|
17,228 |
|
|
25,000 |
|
Stock-based compensation
|
|
|
152,421 |
|
|
—
|
|
Salary expense
|
|
|
132,054 |
|
|
133,811 |
|
Professional fee
|
|
|
184,791 |
|
|
293,934 |
|
Insurance expense
|
|
|
86,690 |
|
|
88,456 |
|
Other general and administrative fee
|
|
|
102,965 |
|
|
34,536 |
|
Loss before income tax
|
|
|
4,801,149 |
|
|
3,376,737 |
| |
|
|
|
|
|
|
|
Income tax expense
|
|
|
—
|
|
|
—
|
|
Net loss
|
|
$
|
4,801,149 |
|
$
|
3,376,737 |
|
|
|
For the nine months ended
September 30,
|
| |
|
2025
|
|
2024
|
| |
|
(Unaudited)
|
|
(Unaudited)
|
|
Operating expenses:
|
|
|
|
|
|
|
|
Clinical trial related service fee
|
|
$
|
10,125,000 |
|
$
|
6,301,000 |
|
Consulting fee
|
|
|
67,228 |
|
|
75,000 |
|
Stock-based compensation
|
|
|
470,614 |
|
|
—
|
|
Salary expense
|
|
|
392,861 |
|
|
385,360 |
|
Professional fee
|
|
|
945,318 |
|
|
645,238 |
|
Insurance expense
|
|
|
251,383 |
|
|
263,443 |
|
Other general and administrative fee
|
|
|
197,071 |
|
|
125,673 |
|
Loss before income tax
|
|
|
12,449,475 |
|
|
7,795,714 |
| |
|
|
|
|
|
|
|
Income tax expense
|
|
|
863 |
|
|
1,625 |
|
Net loss
|
|
$
|
12,450,338 |
|
$
|
7,797,339 |
|